Intellect Neurosciences, Inc. Issues Letter to Shareholders - GlobeNewswire press release

Alan_T August 23, 2014, 8:42am 1

Shire is developing OX1 as a treatment for Friedreich’s Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.

Via Friedreich Ataxia Scientific News

Topic		Replies	Views
Friedreich’s Ataxia: A Collaboration And Gene Therapy General	6	2085	January 5, 2014
Agilis and Intrexon team up to tackle Friedreich’s Ataxia General	0	1793	January 10, 2014
The US Food and Drug Administration (FDA) has given orphan drug designation to a Friedreich’s ataxia drug called omaveloxolone General	6	1960	July 2, 2017
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich’s Ataxia General	0	1704	June 23, 2017
Regulatory Breakthrough for Potential Freidreich's Ataxia Treatment General	0	1682	August 3, 2017